Errol B. De Souza, Ph.D.
President & CEO
Dr. De Souza is President, Chief Executive Officer and a member of Board of Directors of Neuropore Therapies, a biopharmaceutical company developing disease modifying treatment for Parkinson’s Disease, Alzheimer’s Disease and other neurodegenerative disorders by targeting molecular mechanisms of autophagy and neuro-inflammation to facilitate clearance of misfolded proteins. He has substantial experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences, Nasdaq: NBIX) and served as President and Chief Executive Officer of several public (Biodel, Nasdaq: BIOD; Synaptic Pharmaceutical Corp., Nasdaq: SNAP) and private (Archemix) biotech companies.
Dr. De Souza has raised hundreds of million dollars in capital in private (venture) and public sectors. Also, he has been involved in taking companies public (Neurocrine Biosciences IPO), executed M&A deals including Synaptic Pharmaceuticals sale to H. Lundbeck A/S, and has served in a number of high-ranking R&D roles, including Senior Vice President and U.S. head of R&D for Aventis (now Sanofi; 1998-2002), co-founder and Executive Vice President of Research and Development at Neurocrine Biosciences (1992-1998), and Head of CNS Diseases Research at DuPont Merck (1990 – 1992). He has extensive Board experience and serves or has served on the Board of Directors of several private companies and public companies.
Dr. De Souza received his B.A in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.
Douglas Bonhaus, Ph.D.
Chief Science Officer
Dr. Douglas Bonhaus has served as the Chief Scientific Officer of Neuropore Therapies, Inc. since 2011. Dr. Bonhaus is an established leader in the pharmaceutical industry with more than 25 years of experience building and leading drug discovery organizations dedicated to the discovery and development of new therapeutics for neurological and psychiatric disorders. Before joining Neuropore Therapies, Dr. Bonhaus has held industry positions at Syntex, Roche and ACADIA pharmaceuticals where he served as the Vice President of Biosciences. Dr. Bonhaus was also co-founder and Chief Scientific Officer for Denysias Bioscience, a start-up company focused on developing a novel therapeutic for a psychiatric indication in Parkinson's disease. Key scientific and leadership contributions in these positions have resulted in a number of novel therapeutic agents being advanced to clinical development or the market. He is an inventor on several patents, a principal author on over a hundred peer-reviewed publications and has been awarded a number of NIH and private foundation research grants.
Dr. Bonhaus received his Ph.D. in pharmacology and toxicology from the University of Arizona and completed postdoctoral training in the Department of Medicine at Duke University.
Paul Gotfredson, CPA
Chief Financial Officer
Mr. Gotfredson has served as the Chief Financial Officer of Neuropore Therapies since 2009. Mr. Gotfredson is a financial and accounting professional with significance management experience working with private and public companies. He also advises other early-stage companies on equity and debt financing, financial reporting, operations and corporate governance. Before joining Neuropore Therapies, Mr. Gotfredson held the positions of Director of Finance with Genicon Sciences, a high-growth venture-backed biotech acquired by Life Technologies, Corporate Controller at Molecular Biosystems, a publicly traded biotech acquired by Alliance Pharmaceuticals, and Assistant Controller with Casio Manufacturing Corporation.
Mr. Gotfredson began his career working as an auditor in the San Diego offices of Ernst and Young. He received his BS in Accounting from the University of San Diego in 1989 and was licensed as a CPA in the state of California in 1992.
Wolf Wrasidlo, Ph.D.
Executive Director, Medicinal Chemistry
Dr. Wolfgang Wrasidlo is one of the founding members of Neuropore Therapies Inc. and a research chemist with a distinguished 40 plus year career in academia and the pharmaceutical industry. He has held several senior level positions in academia including Director of the Chemical Biology Program at the UCSD Moores Cancer Center, UCSD School of Medicine, The Scripps Research Institute, Humboldt University Berlin Medical School, University of Tuebingen Children’s Hospital, and Columbia University. He has held positions in industry as a Distinguished Research Fellow at TargeGen, Inc., a Founder and the Head of Research at Brunswick Biotechnetics, a Research Scientist at General Atomics, and a member of the Member- Macromolecular Chemistry Group at the Boeing Scientific Research Institute.
Dr. Wrasidlo received a B.S. in Chemistry from San Diego State University and a Ph.D. in Organic Chemistry from the University of Erlangen and San Diego State University. He has authored over 200 scientific publications and the inventor on over 80 patents or patent applications.
Diana L. Price, Ph.D.
Senior Director, Neurosciences and In Vivo Pharmacology
Dr. Price is the Senior Director of Neurosciences and In Vivo Pharmacology at Neuropore Therapies where she has lead research efforts supporting drug discovery, preclinical development, and translational biomarker studies since 2011.
Dr. Price received her doctorate in Neurosciences from the UCSD School of Medicine in 2000. She conducted a postdoctoral appointment from 2000-2003, and then transitioned to an academic research faculty member at the National Center for Microscopy and Imaging Research at UCSD while conducting collaborative multi-scale imaging, behavioral pharmacology and bioinformatics research in pursuit of characterizing translational models of CNS disorders.
Dr. Price moved to industry in 2007, with a position at ACADIA Pharmaceuticals as a drug-discovery team member for neurological and psychiatric disorders utilizing behavioral pharmacology and neuroanatomical techniques to evaluate drug candidates and provide proof of concept data for preclinical development of Pimavanserin (Nuplazid™) for Parkinson’s and Alzheimer’s disease psychosis.
Martin B. Gill, Ph.D.
Director, In Vitro Pharmacology
Dr. Martin B. Gill joined Neuropore Therapies in 2016 as the Director, In Vitro Pharmacology. Dr. Gill received his doctorate in Neuroscience and Cell Biology from the University of Texas-Medical Branch in 2007 and conducted postdoctoral work from 2007-2009 at Northwestern University, Feinberg School of Medicine. Dr. Gill transitioned to industry in 2009 as a research scientist in Neuroscience Discovery with Eli Lilly supporting target identification/validation and lead optimization efforts. Dr. Gill was a Research Investigator (2011-2013) and Senior Research Investigator (2013-2016) in the Neuroscience Discovery department at Bristol-Myers Squibb (BMS) where he managed a lab of research scientists focused on in vitro/in vivo assay development to support portfolio program progression.